AN INNOVATIVE APPROACH FOR DRUG DISCOVERY
'Theranyx is revolutionising the drug discovery process through the generation of highly specific antibody fragments of a similar pharmacological profile, termed Therabodies™.
A Therabody™ is different from a classical antibody by its capacity to block or activate a protein, modulate its function or induce the internalisation of a targeted receptor.
Our scientific approach allows us to considerably widen the number of targets validated in our platform, and as a consequence, to speed up the developement of novel treatments for numerous diseases.
Theranyx is developing its own therapeutic pipeline and is engaged in collaborative projects with pharmaceutical companies and academic teams in Europe, Asia and the US on a dozen targets for various indications including cancer, pain and arteriosclerosis.
OUR PRIORITY: THE DEVELOPMENT OF INNOVATIVE ANTICANCER TREATMENT
Theranyx’s research is focused on a family of membrane receptors notably underexploited for the development of anticancer treatments: the G protein coupled receptors (GPCRs)
GPCRs constitute the largest family of therapeutic targets encompassing over 360 genes among which many have been described as over-expressed in multiple cancers.
Being the first company to have isolated functional antibody fragments hat modulate either the activation or blockade of GPCR activity, Theranyx wishes to capitalize on this technological breakthrough to develop a portfolio of innovative targets and functional antibodies that have been validated in vivo.